Backed by robust clinical evidence and promising outcomes, Colozo represents a breakthrough in addressing unmet needs of patients and enhancing their quality of life, said Ramana
Dr. Reddy’s Laboratories has launched Linaclotide, a medication for adults suffering from chronic constipation in India.
Hyderabad-based Dr Reddy’s becomes the first pharmaceutical company to receive regulatory approval to launch Linaclotide in India under the brand name Colozo, available in 72 mcg and 145 mcg doses .
Linaclotide is indicated for adults suffering from chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C) in adults, and functional constipation (FC) in paediatric patients aged 6 to 17 years. It is a highly selective agonist of guanylate cyclase-C (GC-C) receptors in the intestine. In India, Linaclotide is approved for the treatment of chronic idiopathic constipation (CIC) in adults.
“The launch of Colozo marks a significant step in our gastrointestinal segment in India and adds to our list of novel and first-in-class drugs after the launch of BixiBat in India last year. Colozo is a differentiated, USFDA-approved solution for chronic constipation,’‘ M V Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy’s said in a release.
“Backed by robust clinical evidence and promising outcomes, Colozo represents a breakthrough in addressing unmet needs of patients and enhancing their quality of life. With Colozo, we continue to strengthen our commitment to deliver advanced therapies that meaningfully improve everyday patient care, in keeping with our goal to serve 1.5 billion patients by 2030,’‘ he added.
Published on August 26, 2025
About the Author
